Many inherited metabolic liver diseases such as Wilson's disease, Gaucher's disease, lipidosis, alpha-1 antitrypsin deficiency, hemochromatosis, tyrosinemia and glycogen storage diseases are cured by successful liver transplantation. YNHTC specializes in genetic testing for liver diseases and treatments that provide comprehensive care for affected patients.
Adult liver transplant services
YNHTC offers comprehensive services to patients suffering from all forms of liver disease, including living donor and deceased donor transplantation, treatment for liver cancer, liver transplantation in HIV-infected individuals, and pre- and post-transplant antiviral therapy to prevent or treat recurrent hepatitis C. Through our acute liver failure program, we can transfer patients to YNHH in a timely manner for transplant evaluation and medical management. In collaboration with the Medical Intensive Care Unit, we offer innovative techniques such as hypothermia therapy for the treatment of acute liver failure.
YNHTC is one of only 13 sites in the U.S. that participates in the NIH-sponsored Acute Liver Failure Study Group. This group follows and plans treatment trials for patients with acute liver urgency and liver failure.
Pediatric liver transplant services
The Pediatric Liver Transplant Program at YNHTC provides leading-edge treatment for children suffering from liver failure and genetic diseases of the liver that result in life-threatening complications. YNHTC is a regional leader in providing pediatric liver transplantation, serving patients from Connecticut and across the United States as well as international referrals. Innovations in surgery include living donor, split, reduced and mono-segment liver transplantation.
The YNHTC Pediatric Liver Transplant team knows that children often have special needs and unique medical complications that require a great deal of care during the transplant process.
Liver cancer program
The Hepatobiliary Cancer Program offers an entire spectrum of therapies for liver cancer, also known as hepatobiliary carcinoma. The program brings a group of specialists together - including hepatobiliary and transplant surgeons, hepatologists, diagnostic and interventional radiologists, pathologists, medical oncologists and nurses - to reach a consensus on the best treatment for each patient. After treatment, the patient receives care to manage the underlying liver disease, preserve liver function and survey for possible recurrence of the cancer.
A combination of interventional radiology and surgical techniques, including ablation therapy, liver resection, new chemotherapeutic options and liver transplantation, are now available; and in certain patients, these treatments can even cure the disease. For patients diagnosed with early disease, liver transplantation can provide the definitive cure for both the cancer and the advanced liver disease that frequently accompanies a diagnosis of cancer.
For patients who do not have advanced liver disease or for patients who cannot receive a liver transplant, surgical resection, ablative therapies such as transarterial chemoembolization or radiofrequency ablation (RFA) can provide excellent survival rates for the appropriate candidates.
Traditional chemotherapy still has little role in treatment of liver cancer, but new biological agents are being tested to target specific intracellular mechanisms of the cancerous cell.
Learn more about our gastrointestinal cancers program at Smilow Cancer Hospital at Yale-New Haven.